Revenue
No reported data
Regencell Bioscience Holdings Ltd (RGC)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Research & development | $948,289 | $1.1M | $1.6M | $2.5M | $438,323 | $386,230 | $228,223 |
| Operating expenses | $3.8M | $4.7M | $6.3M | $7.6M | $1.4M | $812,371 | $390,990 |
| Operating income | −$3.8M | −$4.7M | −$6.3M | −$7.6M | −$1.4M | −$812,371 | −$390,990 |
| EBITDAderived | — | — | — | −$7.0M | — | — | — |
| Net income | −$3.6M | −$4.3M | −$5.9M | −$7.4M | −$1.3M | −$812,371 | −$390,990 |
| Basic EPSper diluted share | -$0.72 | -$0.87 | -$1.19 | -$0.58 | $0.13 | $0.08 | — |
| Diluted EPSper diluted share | -$0.72 | -$0.87 | -$1.19 | -$0.58 | -$0.13 | -$0.08 | — |